To confirm the role of MCL-1 in RAS-mediated resistance to venetoclax, co-treatment with venetoclax and an MCL-1 inhibitor, AZD-5991, significantly reduced AML blasts in mice [11]. Here, MCL1 is linked to acute myeloid leukemia.